Antimicrobial Resistance: Point of Care Diagnostics in Human Health – Phase 2
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit:
Memorial Deadline: Inquire with RGCS
External Deadline: Wednesday 15th, August 2018
Description
Antimicrobial resistance (AMR) is a serious and growing global public threat that requires a global unified response. Governments and health organizations around the world are increasingly paying more attention to the significant threat that AMR poses to modern medicine and the health of the global population. In Canada and around the world, the effectiveness of antimicrobials has been declining due to the development of resistance.
The CIHR AMR initiative aligns with the research component of the existing Federal Framework on AMR, which aims to promote innovation through funding collaborative research and development efforts on antimicrobial resistance both domestically and internationally, as well as Tackling Antimicrobial Resistance and Antimicrobial Use: A Pan-Canadian Framework for Action.
CIHR and partner(s) financial contributions for this initiative are subject to availability of funds. Should CIHR or partner(s) funding levels not be available or are decreased due to unforeseen circumstances, CIHR and partner(s) reserve the right to reduce, defer or suspend financial contributions to grants received as a result of this funding opportunity.
- – The total amount available for this funding opportunity is $2,025,000, enough to fund approximately 3 grants. The maximum amount per grant is $225,000 per year for up to 3 years for a total of $675,000 per grant.
- – Applicants must secure eligible partner contributions (cash or in-kind) to match the CIHR contribution at a minimum of 1:1 ratio. These contributions must exclude any new or existing funding from any sources or grants from the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), the Social Sciences and Humanities Research Council of Canada (SSHRC), the Networks of Centres of Excellence (NCE), and the Canada Research Chairs (CRC) program. As the intent of this phase 2 of POC diagnostics RFA is to bring/evaluate tests in clinical settings, the involvement of meaningful partners (cash and/or in-kind) is central. CIHR will recognize only those in-kind contributions detailed in the application and considered essential to carry out the work. It will be an integral part of the evaluation of the proposal (see below).
Please visit CIHR’s website for additional program information.